A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors
| Autor: | Lin, Lin, Pan, Hongming, Li, Xingya, Zhao, Chengling, Sun, Jiangtao, Hu, Xingsheng, Zhang, Yiping, Wang, Mengzhao, Ren, Xiubao, Luo, Xiaoyong, Shan, Guoyong, Hui, Ai-Min, Wu, Zhuli, Liu, Huilong, Tian, Ling, Shi, Yuankai |
|---|---|
| Zdroj: | In Lung Cancer April 2022 166:98-106 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect